<p><strong>关键里程碑推动专利组合翻倍至全球 200 项以上 – 将 Propanc 定位为转移性癌症预防领域的长期领导者</strong></p>
<p>澳大利亚墨尔本，2026 年 1 月 27 日（GLOBE NEWSWIRE）-- Propanc Biopharma, Inc.（纳斯达克：PPCB）（“Propanc” 或 “公司”），一家专注于开发慢性疾病新疗法的生物制药公司，包括复发性和转移性癌症，今天宣布在过去两个月内向澳大利亚知识产权局提交了第四项新的临时专利申请。该最新申请专注于胰腺前酶——胰蛋白酶原和糜蛋白酶原的创新配方，这些是 Propanc 的主要资产 PRP 中的活性成分——解决了稳定性、储存、冷冻/解冻循环和全球运输等关键挑战。这些进展克服了开发这些前酶在生物医学应用（包括癌症和其他慢性疾病）中可行药物组合的长期障碍。</p>
<p>“在如此短的时间内提交四项临时专利申请，突显了我们保护和扩展我们开创性前酶技术的坚定决心，” Propanc 首席执行官 James Nathanielsz 先生表示。“随着这些申请在主要全球市场进入国家阶段，我们预计我们的知识产权组合将翻倍——从大约 90 项增加到 200 项以上——涵盖组合、配方、治疗方法和新的治疗适应症。”</p>
<p>这一快速的知识产权扩展巩固了 Propanc 在一种新型治疗范式中的主导地位：利用前酶针对和预防固体肿瘤的转移——特别是那些选择有限且标准治疗通常伴随严重副作用的侵袭性、分化差的癌症。</p>
<p>“这些专利申请将确保我们在一个有巨大未满足需求的领域中在未来二十年的领导地位，” Nathanielsz 先生继续说道。“我们正在建立一个不可动摇的基础，以推动我们的主要资产 PRP 进入针对晚期癌症患者的里程碑式 1b 期首次人体研究。准备工作正在迅速推进，我们预计在临床路径和更广泛的管道方面会有更多令人兴奋的更新。”</p>
<p>Propanc 的 PRP 是一种专有的静脉注射配方，旨在选择性攻击癌症干细胞和循环肿瘤细胞，同时保护健康组织——提供作为长期疗法的潜力，以在不使用传统化疗或放射治疗的毒性的情况下阻止复发和转移。</p>
<p><strong>关于 Propanc Biopharma, Inc.</strong></p>
<p>Propanc Biopharma, Inc.（纳斯达克：PPCB）正在开发一种新方法，通过前酶激活来预防癌症复发和转移，目标是消灭癌症干细胞。公司的主要产品候选 PRP 旨在解决癌症增殖和扩散的根本驱动因素。</p>
<p><strong>更多信息：</strong> www.propanc.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中所有非历史性的声明均为前瞻性声明，包括与公司对其市场地位和市场机会的预期、产品开发、制造和销售的预期和计划，以及与其合作伙伴和投资者的关系相关的声明，这些声明是基于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的安全港条款。这些声明不是历史事实，而是基于公司当前的预期、估计和关于其业务、运营及其他类似或相关因素的预测。诸如 “可能”、“将”、“能够”、“会”、“应该”、“预期”、“预测”、“潜在”、“继续”、“期望”、“打算”、“计划”、“项目”、“相信”、“估计” 等词语用于识别这些前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性和假设，这些因素难以或不可能预测，并且在某些情况下超出了公司的控制范围。前瞻性声明并不是未来行动或表现的保证。实际结果可能因多种因素而与前瞻性声明中的结果有实质性差异，包括但不限于与市场条件相关的风险和不确定性，以及在与拟议发行相关的招股说明书中描述的 “风险因素” 以及公司向 SEC 提交的文件中描述的那些风险。公司没有义务修订或更新本声明中的信息，以反映未来的事件或情况，即使新信息变得可用。</p>
<p><strong>公司：</strong></p>
<p>Propanc Biopharma, Inc.</p>
<p>James Nathanielsz</p>
<p>+61-3-9882-0780</p>
<p>info@propanc.com</p>
<p><strong>投资者联系：</strong></p>
<p>irteam@propanc.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME16QXlNaU0zTXpreU5qUTJJekl5T1RFeE1UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME16QXlNaU0zTXpreU5qUTJJekl5T1RFeE1UST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png"/></p>

PPCB

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

<p>Propanc Biopharma, Inc. 已在两个月内提交了第四份临时专利申请，旨在将其专利组合扩大至全球超过 200 项。该申请专注于胰腺前酶的创新配方，解决了生物医学应用中，特别是在癌症治疗方面的稳定性和运输挑战。首席执行官 James Nathanielsz 强调了公司保护其前酶技术的承诺，该技术针对癌症干细胞，旨在防止转移。公司正在为其主要资产 PRP 的 1b 期研究做准备，该研究旨在提供一种比传统癌症疗法毒性更低的替代方案</p>

<p><strong>Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention</strong></p>
<div class="lb-trans"><p><strong>关键里程碑推动专利组合翻倍至全球 200 项以上 – 将 Propanc 定位为转移性癌症预防领域的长期领导者</strong></p>
</div><p>MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on innovative formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components in Propanc’s lead asset, PRP — addressing critical challenges in stability, storage, freeze/thaw cycling, and global transport. These advancements overcome longstanding barriers in developing viable pharmaceutical compositions of these proenzymes for biomedical applications, including cancer and other chronic diseases.</p>
<div class="lb-trans"><p>澳大利亚墨尔本，2026 年 1 月 27 日（GLOBE NEWSWIRE）-- Propanc Biopharma, Inc.（纳斯达克：PPCB）（“Propanc” 或 “公司”），一家专注于开发慢性疾病新疗法的生物制药公司，包括复发性和转移性癌症，今天宣布在过去两个月内向澳大利亚知识产权局提交了第四项新的临时专利申请。该最新申请专注于胰腺前酶——胰蛋白酶原和糜蛋白酶原的创新配方，这些是 Propanc 的主要资产 PRP 中的活性成分——解决了稳定性、储存、冷冻/解冻循环和全球运输等关键挑战。这些进展克服了开发这些前酶在生物医学应用（包括癌症和其他慢性疾病）中可行药物组合的长期障碍。</p>
</div><p>“Filing four provisional patent applications in such a short timeframe underscores our relentless drive to protect and expand our groundbreaking proenzyme technology,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “As these applications advance to national phase entry across major global markets, we expect to more than double our IP portfolio — from approximately 90 to over 200 patents — covering compositions, formulations, treatment methods, and new therapeutic indications.”</p>
<div class="lb-trans"><p>“在如此短的时间内提交四项临时专利申请，突显了我们保护和扩展我们开创性前酶技术的坚定决心，” Propanc 首席执行官 James Nathanielsz 先生表示。“随着这些申请在主要全球市场进入国家阶段，我们预计我们的知识产权组合将翻倍——从大约 90 项增加到 200 项以上——涵盖组合、配方、治疗方法和新的治疗适应症。”</p>
</div><p>This rapid IP expansion reinforces Propanc’s commanding position in a novel therapeutic paradigm: using proenzymes to target and prevent metastasis from solid tumors — particularly aggressive, poorly differentiated cancers where options remain limited and standard treatments often carry severe side effects.</p>
<div class="lb-trans"><p>这一快速的知识产权扩展巩固了 Propanc 在一种新型治疗范式中的主导地位：利用前酶针对和预防固体肿瘤的转移——特别是那些选择有限且标准治疗通常伴随严重副作用的侵袭性、分化差的癌症。</p>
</div><p>“These patents applications will secure our leadership for the next two decades in a field with enormous unmet need,” Mr. Nathanielsz continued. “We’re building an unassailable foundation to propel our lead asset, PRP, into a landmark Phase 1b First-In-Human study in advanced cancer patients. Preparations are advancing rapidly, and we anticipate further exciting updates on our clinical pathway and broader pipeline in the near term.”</p>
<div class="lb-trans"><p>“这些专利申请将确保我们在一个有巨大未满足需求的领域中在未来二十年的领导地位，” Nathanielsz 先生继续说道。“我们正在建立一个不可动摇的基础，以推动我们的主要资产 PRP 进入针对晚期癌症患者的里程碑式 1b 期首次人体研究。准备工作正在迅速推进，我们预计在临床路径和更广泛的管道方面会有更多令人兴奋的更新。”</p>
</div><p>Propanc’s PRP is a proprietary intravenous formulation designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue — offering potential as a long-term therapy to halt recurrence and metastasis without the toxicity of conventional chemotherapy or radiation.</p>
<div class="lb-trans"><p>Propanc 的 PRP 是一种专有的静脉注射配方，旨在选择性攻击癌症干细胞和循环肿瘤细胞，同时保护健康组织——提供作为长期疗法的潜力，以在不使用传统化疗或放射治疗的毒性的情况下阻止复发和转移。</p>
</div><p><strong>About Propanc Biopharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Propanc Biopharma, Inc.</strong></p>
</div><p>Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.</p>
<div class="lb-trans"><p>Propanc Biopharma, Inc.（纳斯达克：PPCB）正在开发一种新方法，通过前酶激活来预防癌症复发和转移，目标是消灭癌症干细胞。公司的主要产品候选 PRP 旨在解决癌症增殖和扩散的根本驱动因素。</p>
</div><p><strong>More information:</strong> www.propanc.com</p>
<div class="lb-trans"><p><strong>更多信息：</strong> www.propanc.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.</p>
<div class="lb-trans"><p>本新闻稿中所有非历史性的声明均为前瞻性声明，包括与公司对其市场地位和市场机会的预期、产品开发、制造和销售的预期和计划，以及与其合作伙伴和投资者的关系相关的声明，这些声明是基于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的安全港条款。这些声明不是历史事实，而是基于公司当前的预期、估计和关于其业务、运营及其他类似或相关因素的预测。诸如 “可能”、“将”、“能够”、“会”、“应该”、“预期”、“预测”、“潜在”、“继续”、“期望”、“打算”、“计划”、“项目”、“相信”、“估计” 等词语用于识别这些前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性和假设，这些因素难以或不可能预测，并且在某些情况下超出了公司的控制范围。前瞻性声明并不是未来行动或表现的保证。实际结果可能因多种因素而与前瞻性声明中的结果有实质性差异，包括但不限于与市场条件相关的风险和不确定性，以及在与拟议发行相关的招股说明书中描述的 “风险因素” 以及公司向 SEC 提交的文件中描述的那些风险。公司没有义务修订或更新本声明中的信息，以反映未来的事件或情况，即使新信息变得可用。</p>
</div><p><strong>Company:</strong></p>
<div class="lb-trans"><p><strong>公司：</strong></p>
</div><p>Propanc Biopharma, Inc.</p>
<div class="lb-trans"><p>Propanc Biopharma, Inc.</p>
</div><p>James Nathanielsz</p>
<div class="lb-trans"><p>James Nathanielsz</p>
</div><p>+61-3-9882-0780</p>
<div class="lb-trans"><p>+61-3-9882-0780</p>
</div><p>info@propanc.com</p>
<div class="lb-trans"><p>info@propanc.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>irteam@propanc.com</p>
<div class="lb-trans"><p>irteam@propanc.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME16QXlNaU0zTXpreU5qUTJJekl5T1RFeE1UST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0MzAyMiM3MzkyNjQ2IzIyOTExMTI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png"/></p>

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations | PPCB Stock News

StockTitan

Propanc Biopharma

Propanc Biopharma 加快知识产权发展：在短短两个月内提交第四项临时专利申请——加强对突破性前酶配方的全球保护 | PPCB 股票新闻